États-Unis · Plateformes & données · MarketBeat

Krystal Biotech (NASDAQ:KRYS) Given New $412.00 Price Target at Citigroup

Publié par MarketBeat · États-Unis il y a 1 h

Citigroup decreased their price objective on shares of Krystal Biotech from $416.00 to $412.00 and set a "buy" rating on the stock in a report on Tuesday.

Lire l'article complet sur MarketBeat Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.marketbeat.com)

Krystal Biotech (NASDAQ:KRYS) Given New $412.00 Price Target at Citigroup

À lire aussi

AppLovin Q3 2026 earnings preview: Revenue expected to rise Y/Y

Chegg (CHGG) Q3 2026 Earnings Call Transcript

‘It’s good to be old’: I’ve been invited to a dozen free meals that turn into annuity sales pitches. Should I stop going?

Stock market after midterm elections: What S&P 500 history shows

Toncoin (TON) Price Prediction 2025, 2026, 2027-2030

Penguin Solutions to Showcase Full-Stack AI Factory Platform Innovations at SC26

Krystal Biotech (NASDAQ:KRYS) Given New $412.00 Price Target at Citigroup

Partager

À lire aussi

AppLovin Q3 2026 earnings preview: Revenue expected to rise Y/Y

Chegg (CHGG) Q3 2026 Earnings Call Transcript

‘It’s good to be old’: I’ve been invited to a dozen free meals that turn into annuity sales pitches. Should I stop going?

Stock market after midterm elections: What S&P 500 history shows

Toncoin (TON) Price Prediction 2025, 2026, 2027-2030

Penguin Solutions to Showcase Full-Stack AI Factory Platform Innovations at SC26